Oxford Biomedica notes the announcement that Kymriah® has received FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Oxford, UK – 22nd April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes the announcement from Novartis that the US…